The UK company insists that by the end of the year a partner will have been found for its microbiome project to prevent C difficile infections.
The clinical hold for Biomarin’s phenylketonuria project comes on the heels of an FDA adcom to discuss gene therapy toxicity.
The average takeout premium for a research-stage biotech is tracking at 100% this year, the latest data show.
The microbiome-focused group has some explaining to do.
A global pandemic has done nothing to crimp M&A premiums, with acquirers forced to swallow ever higher price tags.
A few multi-billion-dollar deals got done in the third quarter, but 2020’s acquisition scene still looks anaemic.